Business Update

Bio‑Works Technologies will begin issuing quarterly business updates starting with Q4 2025 and reported strong preliminary top‑line and order metrics: Q4 2025 net sales of SEK 23.7m (vs SEK 2.6m prior), last two quarters SEK 40.4m (vs 12.5m) and last four quarters SEK 62.5m (vs 25.5m). Order intake for Q4 2025 was SEK 25.6m (vs 6.1m) and the order book stood at SEK 32.5m on 2025‑12‑31; amounts are preliminary. The cadence change improves transparency for investors and the reported numbers indicate materially higher sales and bookings year‑over‑year.

Analysis

Market structure: Bio‑Works (BIOWKS) shifting to quarterly business updates and showing Q4’25 preliminary net sales 23.7 MSEK (vs 2.6 MSEK prior) and order intake 25.6 MSEK signals a step‑function demand pickup for purification consumables and small‑scale equipment. Winners: Bio‑Works, regional distributors in Europe/NA/Asia, and niche contract manufacturers that supply chromatography components; losers: generic industrial suppliers with no life‑science exposure and incumbents facing faster competition on mid‑market accounts. Increased transparency will likely compress bid/ask spreads and attract institutional small‑cap life‑science investors, improving liquidity over 3–12 months.

Risk assessment: Key tail risks include a large customer canceling orders (single‑order concentration), manufacturing quality failures triggering recalls (ISO implications), or need for expansion capex leading to equity dilution; probability medium but impact high. Immediate (days) market moves will be info‑flow driven; short term (weeks–months) depends on orderbook conversion rates (>30% conversion within 1–2 quarters is a positive threshold); long term (12–24 months) hinges on sustained recurring revenue and distribution expansion. Hidden dependencies: FX exposure to SEK, distributor concentration, and supply chain for resins/columns that could elongate lead times and force price concessions.

Trade implications: Establish a measured long exposure to BIOWKS sized 2–3% of equity risky capital if order‑to‑revenue conversion exceeds 25–30% in the next two quarters; use a 12‑month horizon and a 15% hard stop. Implement a relative value pair: long BIOWKS / short Sartorius (SRT3.DE) small size (0.5–1% net) to isolate company‑specific growth vs sector beta. If options exist, prefer a limited‑risk call spread (buy ATM, sell call ~+40% strike) expiring 9–12 months to cap downside while retaining upside. Rotate 1–2% portfolio weight from broad industrials into small‑cap Life‑Science Tools names over 4–8 weeks as transparency milestones are met.

Contrarian angles: Consensus may underprice margin expansion potential if Bio‑Works converts one‑off project revenue to recurring consumables sales — a 30–50% gross margin improvement would materially rerate the stock. Conversely, the market can overreact to glowing order intake if orders are front‑loaded; require two sequential quarters of order conversion before committing >3% position size. Historical parallels: small life‑science tools firms re‑rated after proving repeatable commercial scale (6–12 months); failure modes were almost always operational (capacity/capex) not demand.

Key Decisions for Investors

• Establish a 2–3% long position in BIOWKS (Bio‑Works Technologies AB) within 2–6 weeks, conditional on verifying orderbook conversion ≥25% in the next two quarters; set a 12‑month target +40% and a hard stop loss at −15% from entry.
• Implement a limited‑risk options trade if available: buy a 9–12 month ATM call and sell a call at ~+40% (call spread) sized to cap downside to ≤3% of portfolio value; roll or unwind upon two consecutive quarters of weak conversion (<15%).
• Run a pair trade: long BIOWKS (1–2% position) vs short Sartorius (SRT3.DE) sized 0.5–1% net to isolate company‑specific upside; review after Q1’26 business update and rebalance if BIOWKS order intake growth >50% QoQ.
• Reallocate 1–2% from broad industrial exposures into small‑cap Life‑Science Tools over 4–8 weeks, but pause further buys if FX‑adjusted revenue growth falls below 20% YoY or if distributor concentration >40% of sales is disclosed.